Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γ

Christal D. Sohl, Michal R. Szymanski, Andrea C. Mislak, Christie K. Shumate, Sheida Amiralaei, Raymond F. Schinazi, Karen S. Anderson, Yuhui Yin

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Nucleoside analog reverse transcriptase inhibitors (NRTIs) are the essential components of highly active antiretroviral (HAART) therapy targeting HIV reverse transcriptase (RT). NRTI triphosphates (NRTI-TP), the biologically active forms, act as chain terminators of viral DNA synthesis. Unfortunately, NRTIs also inhibit human mitochondrial DNA polymerase (Pol γ), causing unwanted mitochondrial toxicity. Understanding the structural and mechanistic differences between Pol γ and RT in response to NRTIs will provide invaluable insight to aid in designing more effective drugs with lower toxicity. The NRTIs emtricitabine [(-)-2,3′-dideoxy-5-fluoro-3′-thiacytidine, (-)-FTC] and lamivudine, [(-)-2,3′-dideoxy-3′-thiacytidine, (-)-3TC] are both potent RT inhibitors, but Pol γ discriminates against (-)-FTC-TP by two orders of magnitude better than (-)-3TC-TP. Furthermore, although (-)-FTC-TP is only slightly more potent against HIV RT than its enantiomer (+)-FTC-TP, it is discriminated by human Pol γ four orders of magnitude more efficiently than (+)-FTC-TP. As a result, (-)-FTC is a much less toxic NRTI. Here, we present the structural and kinetic basis for this striking difference by identifying the discriminator residues of drug selectivity in both viral and human enzymes responsible for substrate selection and inhibitor specificity. For the first time, to our knowledge, this work illuminates the mechanism of (-)-FTC-TP differential selectivity and provides a structural scaffold for development of novel NRTIs with lower toxicity.

Original languageEnglish (US)
Pages (from-to)8596-8601
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume112
Issue number28
DOIs
StatePublished - Jul 14 2015

Fingerprint

Reverse Transcriptase Inhibitors
DNA-Directed DNA Polymerase
Mitochondrial DNA
Nucleosides
Nucleotides
HIV Reverse Transcriptase
Drug Residues
Lamivudine
Poisons
RNA-Directed DNA Polymerase
Highly Active Antiretroviral Therapy
Viral DNA
Enzymes

Keywords

  • Drug efficacy and toxicity
  • HIV reverse transcriptase
  • Human mitochondrial DNA polymerase
  • Mitochondrial toxicity
  • Nucleoside reverse transcriptase inhibitors

ASJC Scopus subject areas

  • General

Cite this

Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γ. / Sohl, Christal D.; Szymanski, Michal R.; Mislak, Andrea C.; Shumate, Christie K.; Amiralaei, Sheida; Schinazi, Raymond F.; Anderson, Karen S.; Yin, Yuhui.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 112, No. 28, 14.07.2015, p. 8596-8601.

Research output: Contribution to journalArticle

Sohl, Christal D. ; Szymanski, Michal R. ; Mislak, Andrea C. ; Shumate, Christie K. ; Amiralaei, Sheida ; Schinazi, Raymond F. ; Anderson, Karen S. ; Yin, Yuhui. / Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γ. In: Proceedings of the National Academy of Sciences of the United States of America. 2015 ; Vol. 112, No. 28. pp. 8596-8601.
@article{5cad7ef096504fc485758f3963e35519,
title = "Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γ",
abstract = "Nucleoside analog reverse transcriptase inhibitors (NRTIs) are the essential components of highly active antiretroviral (HAART) therapy targeting HIV reverse transcriptase (RT). NRTI triphosphates (NRTI-TP), the biologically active forms, act as chain terminators of viral DNA synthesis. Unfortunately, NRTIs also inhibit human mitochondrial DNA polymerase (Pol γ), causing unwanted mitochondrial toxicity. Understanding the structural and mechanistic differences between Pol γ and RT in response to NRTIs will provide invaluable insight to aid in designing more effective drugs with lower toxicity. The NRTIs emtricitabine [(-)-2,3′-dideoxy-5-fluoro-3′-thiacytidine, (-)-FTC] and lamivudine, [(-)-2,3′-dideoxy-3′-thiacytidine, (-)-3TC] are both potent RT inhibitors, but Pol γ discriminates against (-)-FTC-TP by two orders of magnitude better than (-)-3TC-TP. Furthermore, although (-)-FTC-TP is only slightly more potent against HIV RT than its enantiomer (+)-FTC-TP, it is discriminated by human Pol γ four orders of magnitude more efficiently than (+)-FTC-TP. As a result, (-)-FTC is a much less toxic NRTI. Here, we present the structural and kinetic basis for this striking difference by identifying the discriminator residues of drug selectivity in both viral and human enzymes responsible for substrate selection and inhibitor specificity. For the first time, to our knowledge, this work illuminates the mechanism of (-)-FTC-TP differential selectivity and provides a structural scaffold for development of novel NRTIs with lower toxicity.",
keywords = "Drug efficacy and toxicity, HIV reverse transcriptase, Human mitochondrial DNA polymerase, Mitochondrial toxicity, Nucleoside reverse transcriptase inhibitors",
author = "Sohl, {Christal D.} and Szymanski, {Michal R.} and Mislak, {Andrea C.} and Shumate, {Christie K.} and Sheida Amiralaei and Schinazi, {Raymond F.} and Anderson, {Karen S.} and Yuhui Yin",
year = "2015",
month = "7",
day = "14",
doi = "10.1073/pnas.1421733112",
language = "English (US)",
volume = "112",
pages = "8596--8601",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "28",

}

TY - JOUR

T1 - Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γ

AU - Sohl, Christal D.

AU - Szymanski, Michal R.

AU - Mislak, Andrea C.

AU - Shumate, Christie K.

AU - Amiralaei, Sheida

AU - Schinazi, Raymond F.

AU - Anderson, Karen S.

AU - Yin, Yuhui

PY - 2015/7/14

Y1 - 2015/7/14

N2 - Nucleoside analog reverse transcriptase inhibitors (NRTIs) are the essential components of highly active antiretroviral (HAART) therapy targeting HIV reverse transcriptase (RT). NRTI triphosphates (NRTI-TP), the biologically active forms, act as chain terminators of viral DNA synthesis. Unfortunately, NRTIs also inhibit human mitochondrial DNA polymerase (Pol γ), causing unwanted mitochondrial toxicity. Understanding the structural and mechanistic differences between Pol γ and RT in response to NRTIs will provide invaluable insight to aid in designing more effective drugs with lower toxicity. The NRTIs emtricitabine [(-)-2,3′-dideoxy-5-fluoro-3′-thiacytidine, (-)-FTC] and lamivudine, [(-)-2,3′-dideoxy-3′-thiacytidine, (-)-3TC] are both potent RT inhibitors, but Pol γ discriminates against (-)-FTC-TP by two orders of magnitude better than (-)-3TC-TP. Furthermore, although (-)-FTC-TP is only slightly more potent against HIV RT than its enantiomer (+)-FTC-TP, it is discriminated by human Pol γ four orders of magnitude more efficiently than (+)-FTC-TP. As a result, (-)-FTC is a much less toxic NRTI. Here, we present the structural and kinetic basis for this striking difference by identifying the discriminator residues of drug selectivity in both viral and human enzymes responsible for substrate selection and inhibitor specificity. For the first time, to our knowledge, this work illuminates the mechanism of (-)-FTC-TP differential selectivity and provides a structural scaffold for development of novel NRTIs with lower toxicity.

AB - Nucleoside analog reverse transcriptase inhibitors (NRTIs) are the essential components of highly active antiretroviral (HAART) therapy targeting HIV reverse transcriptase (RT). NRTI triphosphates (NRTI-TP), the biologically active forms, act as chain terminators of viral DNA synthesis. Unfortunately, NRTIs also inhibit human mitochondrial DNA polymerase (Pol γ), causing unwanted mitochondrial toxicity. Understanding the structural and mechanistic differences between Pol γ and RT in response to NRTIs will provide invaluable insight to aid in designing more effective drugs with lower toxicity. The NRTIs emtricitabine [(-)-2,3′-dideoxy-5-fluoro-3′-thiacytidine, (-)-FTC] and lamivudine, [(-)-2,3′-dideoxy-3′-thiacytidine, (-)-3TC] are both potent RT inhibitors, but Pol γ discriminates against (-)-FTC-TP by two orders of magnitude better than (-)-3TC-TP. Furthermore, although (-)-FTC-TP is only slightly more potent against HIV RT than its enantiomer (+)-FTC-TP, it is discriminated by human Pol γ four orders of magnitude more efficiently than (+)-FTC-TP. As a result, (-)-FTC is a much less toxic NRTI. Here, we present the structural and kinetic basis for this striking difference by identifying the discriminator residues of drug selectivity in both viral and human enzymes responsible for substrate selection and inhibitor specificity. For the first time, to our knowledge, this work illuminates the mechanism of (-)-FTC-TP differential selectivity and provides a structural scaffold for development of novel NRTIs with lower toxicity.

KW - Drug efficacy and toxicity

KW - HIV reverse transcriptase

KW - Human mitochondrial DNA polymerase

KW - Mitochondrial toxicity

KW - Nucleoside reverse transcriptase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84937153345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937153345&partnerID=8YFLogxK

U2 - 10.1073/pnas.1421733112

DO - 10.1073/pnas.1421733112

M3 - Article

VL - 112

SP - 8596

EP - 8601

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 28

ER -